Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: Report of three cases

被引：18

作者：

Garcia, VD

Bonamigo, JS

Neumann, J

Fogliatto, L

Gaiger, AM

Garcia, CD

Barros, V

Keitel, E

Bittar, AE

Santos, AF

Roithmann, S

机构：

[1] Fundacao Fac Fed Ciencias Med, Porto Alegre, RS, Brazil

[2] Santa Casa Hosp, Porto Alegre, RS, Brazil

来源：

TRANSPLANTATION PROCEEDINGS | 2002年 / 34卷 / 07期

关键词：

D O I：

10.1016/S0041-1345(02)03511-X

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2993 / 2995

页数：3

共 18 条

[1] Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation [J].

Cook, RC ;

Connors, JM ;

Gascoyne, RD ;

Fradet, G ;

Levy, RD .

LANCET, 1999, 354 (9191) :1698-1699

[2] Lymphoproliferative disorders after organ transplantation in children [J].

Dror, Y ;

Greenberg, M ;

Taylor, G ;

Superina, R ;

Hébert, D ;

West, L ;

Connolly, B ;

Sena, L ;

Allen, U ;

Weitzman, S .

TRANSPLANTATION, 1999, 67 (07) :990-998

[3] Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders [J].

Faye, A ;

Van Den Abeele, T ;

Peuchmaur, M ;

MAthieu-Boue, A ;

Vilmer, E .

LANCET, 1998, 352 (9136) :1285-1285

[4] Rituximab:: An insider's historical perspective [J].

Grillo-López, AJ .

SEMINARS IN ONCOLOGY, 2000, 27 (06) :9-16

[5]

HANTO DW, 1985, TRANSPLANT P, V17, P89

[6] CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation [J].

Kuehnie, I ;

Huls, MH ;

Liu, ZS ;

Semmelmann, M ;

Krance, RA ;

Brenner, MK ;

Rooney, CM ;

Heslop, HE .

BLOOD, 2000, 95 (04) :1502-1505

[7] The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo:: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders [J].

Majewski, M ;

Korecka, M ;

Kossev, P ;

Li, SY ;

Goldman, J ;

Moore, J ;

Silberstein, LE ;

Nowell, PC ;

Schuler, W ;

Shaw, LM ;

Wasik, MA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) :4285-4290

[8] RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL-DEATH IN B-LYMPHOMA-CELLS [J].

MUTHUKKUMAR, S ;

RAMESH, TM ;

BONDADA, S .

TRANSPLANTATION, 1995, 60 (03) :264-270

[9] Treatment of lymphoproliferative disease with rituximab [J].

Niedermeyer, J ;

Hoffmeyer, F ;

Hertenstein, B ;

Hoeper, MM ;

Fabel, H .

LANCET, 2000, 355 (9202) :499-499

[10] Successful treatment of aggressive post transplant lymphoproliferative disorder using Rituximab [J].

O'dwyer, ME ;

Launder, T ;

Rabkin, JM ;

Nichols, CR .

LEUKEMIA & LYMPHOMA, 2000, 39 (3-4) :411-419

← 1 2 →